Phase II Trial of Paricalcitol and Hydroxychloroquine (PH) Combination With Gemcitabine and Nab-Paclitaxel in Advanced or Metastatic Pancreatic Cancer
Latest Information Update: 17 Jan 2024
At a glance
- Drugs Gemcitabine (Primary) ; Hydroxychloroquine (Primary) ; Paclitaxel (Primary) ; Paricalcitol (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 09 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 09 Jan 2024 Planned primary completion date changed from 14 Aug 2023 to 14 Aug 2024.
- 03 Mar 2023 Planned End Date changed from 14 Aug 2023 to 14 Aug 2024.